This discovery stimulated preclinical immunogenic targeting of RHAMM in mouse glioma and melanoma models wherein mice received either dendritic cells pulsed with HMMR mRNA or a DNA-based xenopus RHAMM (xRHAMM), respectively (120, 121). The gene discussed is HMMR; the disease is glioma.